Purine nucleosides

US7199127B2 · kind B2 · utility

Assignees

• THE UNITED STATES OF AMERICA, represented by the Secretary, Department of Health and Human Services · US
• Ewha Womans University · KR

Inventors

• Lak Shin Jeong · Seoul, KR
• Kenneth A. Jacobson · Silver Spring, US
• Hyung Ryong Moon · Busan, KR
• Hea Ok Kim · Seoul, KR

Key dates

• Filing date: Oct 24, 2003
• Grant date: Apr 3, 2007
• Expiry date: Oct 24, 2023

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07H19/167
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Disclosed are purine nucleoside compounds that are selective to A3 adenosine receptors and are useful for the treatment of cancer and inflammatory diseases. The compounds are shown by the following general formula (I), including isomers thereof:wherein X is sulfur or oxygen; R1 is hydrogen, alkyl, benzyl, halobenzyl, or phenylalkyl; R2 is hydrogen, halogen, alkoxy, alkenyl, alkynyl, alkylthio, or thio; R3 and R3′ are hydrogen, hydroxyalkyl, alkoxycarbonyl, or alkylaminocarbonyl, whereas R3 and R3′ do not have identical substituents simultaneously; and R4 is hydrogen or alkyl. Also disclosed are a pharmaceutical composition comprising a compound of formula (I), an isomer, or its pharmacologically acceptable salt as an active ingredient and a method for preventing or treating various diseases, state, or condition, including asthma, inflammation, cerebral ischemia, heart diseases, and cancer.